Inhibrx Inc. (INBX) NASDAQ
$34.38 0.25 (0.73%)
Market Cap: $1.62B
As of 04/24/24 04:00 PM EDT. Market closed.
Inhibrx Inc. (INBX)
NASDAQ
$34.38
0.25 (0.73%)
Market Cap: $1.62B
As of 04/24/24 04:00 PM EDT. Market closed.
Add to Portfolio
development of ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Mark Paul Lappe
Full Time Employees
134
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Mark Paul Lappe
Full Time Employees
134
URL
Address
11025 N. Torrey Pines Road, Suite 200, La Jolla, California, La Jolla, 92037.
PRICE CHART FOR INHIBRX INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$34.15
Previous Close
$34.13
Days Range
$34.09 - $34.47
52 week range
$14.31 - $39.79
Volume
218,293
Avg. Volume (30 days)
410,260
Market Cap
$1.62B
Dividend Yield
-
P/E
(6.70)
Shares Outstanding
47,392,447
Open
$34.15
Previous Close
$34.13
Days Range
$34.09 - $34.47
52 week range
$14.31 - $39.79
Volume
218,293
Avg. Volume (30 days)
410,260
Market Cap
$1.62B
Dividend Yield
-
P/E
(6.70)
Shares Outstanding
47,392,447
FINANCIAL STATEMENTS FOR INHIBRX INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR INHIBRX INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| VIKING GLOBAL INVESTORS LP | 10% Owner | Aug 28, 2023 | Buy | $19.35 | 511,627 | 9,899,983 | 511,627 | Aug 30, 2023, 08:44 PM |
| Lappe Mark | Chief Executive Officer | Feb 28, 2023 | Sale | $25.02 | 60 | 1,501 | 2,486,192 | Mar 01, 2023, 04:41 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Feb 02, 2023 | Sale | $25.45 | 11,250 | 286,355 | 2,076,683 | Feb 02, 2023, 07:26 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Feb 01, 2023 | Sale | $24.73 | 28,750 | 710,856 | 2,102,104 | Feb 02, 2023, 07:26 PM |
| Lappe Mark | Chief Executive Officer | Jan 24, 2023 | Sale | $25.72 | 4,335 | 111,478 | 2,486,315 | Jan 24, 2023, 06:46 PM |
| Lappe Mark | Chief Executive Officer | Jan 23, 2023 | Sale | $25.36 | 21,665 | 549,364 | 2,490,587 | Jan 24, 2023, 06:46 PM |
| Kayyem Jon Faiz | Director | Jan 23, 2023 | Sale | $25.26 | 9,500 | 239,999 | 3,224,301 | Jan 23, 2023, 06:10 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Jan 03, 2023 | Sale | $23.77 | 32,895 | 781,770 | 2,133,340 | Jan 04, 2023, 05:53 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Jan 04, 2023 | Sale | $23.48 | 7,105 | 166,829 | 2,118,556 | Jan 04, 2023, 05:53 PM |
| Kayyem Jon Faiz | Director | Dec 21, 2022 | Sale | $27.02 | 9,500 | 256,679 | 3,235,760 | Dec 22, 2022, 04:04 PM |
| Lappe Mark | Chief Executive Officer | Dec 19, 2022 | Sale | $25.56 | 26,000 | 664,443 | 2,513,006 | Dec 20, 2022, 04:59 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Dec 06, 2022 | Sale | $27.22 | 40,000 | 1,088,683 | 2,174,626 | Dec 07, 2022, 04:30 PM |
| Kayyem Jon Faiz | Director | Nov 21, 2022 | Sale | $29.89 | 9,500 | 283,972 | 3,250,068 | Nov 22, 2022, 04:42 PM |
| Lappe Mark | Chief Executive Officer | Nov 17, 2022 | Sale | $27.88 | 26,000 | 724,910 | 2,557,293 | Nov 18, 2022, 05:06 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Nov 01, 2022 | Sale | $33.51 | 40,000 | 1,340,387 | 2,207,902 | Nov 02, 2022, 05:04 PM |
| Kayyem Jon Faiz | Director | Oct 21, 2022 | Sale | $30.13 | 9,500 | 286,232 | 3,258,729 | Oct 24, 2022, 04:36 PM |
| Lappe Mark | Chief Executive Officer | Oct 17, 2022 | Sale | $29.59 | 26,000 | 769,443 | 2,581,271 | Oct 18, 2022, 04:37 PM |
| VIKING GLOBAL INVESTORS LP | 10% Owner | Oct 07, 2022 | Buy | $30.00 | 1,333,333 | 39,999,858 | 2,427,307 | Oct 12, 2022, 04:39 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Oct 04, 2022 | Sale | $27.82 | 40,000 | 1,112,813 | 2,274,105 | Oct 05, 2022, 04:15 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Sep 06, 2022 | Sale | $14.91 | 40,000 | 596,274 | 2,438,046 | Sep 07, 2022, 04:57 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Aug 02, 2022 | Sale | $17.70 | 24,500 | 433,625 | 2,491,053 | Aug 04, 2022, 04:33 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Aug 03, 2022 | Sale | $18.47 | 15,500 | 286,209 | 2,475,553 | Aug 04, 2022, 04:33 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Jul 07, 2022 | Sale | $17.17 | 40,000 | 686,800 | 2,515,553 | Jul 08, 2022, 04:03 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Apr 05, 2022 | Sale | $25.04 | 400 | 10,016 | 2,555,553 | Apr 07, 2022, 04:11 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Mar 24, 2021 | Sale | $19.02 | 17,000 | 323,340 | 2,555,953 | Mar 24, 2021, 07:12 PM |
| Eckelman Brendan P. | Chief Scientific Officer | Feb 16, 2021 | Sale | $25.90 | 17,000 | 440,300 | 2,572,953 | Feb 18, 2021, 05:08 PM |
| Wagner Klaus W. | Chief Medical Officer | Feb 16, 2021 | Sale | $24.32 | 156,474 | 3,805,448 | 234,709 | Feb 18, 2021, 05:06 PM |
| Wagner Klaus W. | Chief Medical Officer | Feb 17, 2021 | Sale | $25.29 | 19,559 | 494,647 | 215,150 | Feb 18, 2021, 05:06 PM |
| VIKING GLOBAL INVESTORS LP | 10% Owner | Aug 26, 2020 | Buy | $18.92 | 180,219 | 3,409,865 | 1,427,307 | Aug 28, 2020, 04:29 PM |
| VIKING GLOBAL INVESTORS LP | 10% Owner | Aug 25, 2020 | Buy | $19.36 | 85,304 | 1,651,687 | 1,247,088 | Aug 25, 2020, 07:47 PM |
| VIKING GLOBAL INVESTORS LP | 10% Owner | Aug 24, 2020 | Buy | $19.43 | 46,161 | 897,001 | 1,161,784 | Aug 25, 2020, 07:47 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| VIKING GLOBAL INVESTORS LP | 10% Owner | 08/28/2023 | 9,899,983 |
| Lappe Mark | Chief Executive Officer | 02/28/2023 | 1,501 |
| Eckelman Brendan P. | Chief Scientific Officer | 02/02/2023 | 286,355 |
| Eckelman Brendan P. | Chief Scientific Officer | 02/01/2023 | 710,856 |
| Lappe Mark | Chief Executive Officer | 01/24/2023 | 111,478 |
| Lappe Mark | Chief Executive Officer | 01/23/2023 | 549,364 |
| Kayyem Jon Faiz | Director | 01/23/2023 | 239,999 |
| Eckelman Brendan P. | Chief Scientific Officer | 01/03/2023 | 781,770 |
| Eckelman Brendan P. | Chief Scientific Officer | 01/04/2023 | 166,829 |
| Kayyem Jon Faiz | Director | 12/21/2022 | 256,679 |
| Lappe Mark | Chief Executive Officer | 12/19/2022 | 664,443 |
| Eckelman Brendan P. | Chief Scientific Officer | 12/06/2022 | 1,088,683 |
| Kayyem Jon Faiz | Director | 11/21/2022 | 283,972 |
| Lappe Mark | Chief Executive Officer | 11/17/2022 | 724,910 |
| Eckelman Brendan P. | Chief Scientific Officer | 11/01/2022 | 1,340,387 |
| Kayyem Jon Faiz | Director | 10/21/2022 | 286,232 |
| Lappe Mark | Chief Executive Officer | 10/17/2022 | 769,443 |
| VIKING GLOBAL INVESTORS LP | 10% Owner | 10/07/2022 | 39,999,858 |
| Eckelman Brendan P. | Chief Scientific Officer | 10/04/2022 | 1,112,813 |
| Eckelman Brendan P. | Chief Scientific Officer | 09/06/2022 | 596,274 |
| Eckelman Brendan P. | Chief Scientific Officer | 08/02/2022 | 433,625 |
| Eckelman Brendan P. | Chief Scientific Officer | 08/03/2022 | 286,209 |
| Eckelman Brendan P. | Chief Scientific Officer | 07/07/2022 | 686,800 |
| Eckelman Brendan P. | Chief Scientific Officer | 04/05/2022 | 10,016 |
| Eckelman Brendan P. | Chief Scientific Officer | 03/24/2021 | 323,340 |
| Eckelman Brendan P. | Chief Scientific Officer | 02/16/2021 | 440,300 |
| Wagner Klaus W. | Chief Medical Officer | 02/16/2021 | 3,805,448 |
| Wagner Klaus W. | Chief Medical Officer | 02/17/2021 | 494,647 |
| VIKING GLOBAL INVESTORS LP | 10% Owner | 08/26/2020 | 3,409,865 |
| VIKING GLOBAL INVESTORS LP | 10% Owner | 08/25/2020 | 1,651,687 |
| VIKING GLOBAL INVESTORS LP | 10% Owner | 08/24/2020 | 897,001 |
Load More Insider Transactions
FUNDS WITH A POSITION IN INHIBRX INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 7,150,826 | 1% | No change | Growth At A Reasonable Price |
| RA CAPITAL MANAGEMENT, L.P. | 4,724,207 | 2.8% | No change | Other |
| BLACKROCK INC. | 2,715,672 | 0.00263% | 6.93% | Other |
| CAPITAL RESEARCH GLOBAL INVESTORS | 712,360 | 0.00666% | -41.69% | Growth At A Reasonable Price |
| GEODE CAPITAL MANAGEMENT, LLC | 687,360 | 0.00273% | 6.38% | Other |
| PLATINUM INVESTMENT MANAGEMENT LTD | 167,763 | 0.26% | -26.75% | Growth At A Reasonable Price, Value |
| CANDRIAM S.C.A. | 135,069 | 0.04% | -12.9% | Other |
| ALPS ADVISORS INC | 33,107 | 0.00989% | New | Other |
| TUDOR INVESTMENT CORP ET AL | 18,379 | 0.00562% | -15.34% | Event Driven, Other |
| ROYCE & ASSOCIATES LP | 12,995 | 0.00456% | New | Value |
CHANGE IN SHARES OUTSTANDING FOR INHIBRX INC
STOCK BUYBACKS FOR INHIBRX INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
14.76%
1Q
06/30/2023
23.99%
2Q
03/31/2023
24.18%
3Q
12/31/2022
24.96%
4Q
09/30/2022
38.49%
5Q
06/30/2022
38.60%
6Q
03/31/2022
38.69%
7Q
12/31/2021
40.23%
8Q
09/30/2021
42.80%
9Q
06/30/2021
43.06%
10Q
03/31/2021
43.39%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR INHIBRX INC
LOADING...